Copson ER, et al. - Researchers undertook a prospective cohort study of patients with young-onset breast cancer primarily to determine the effect of a germline BRCA1 or BRCA2 mutation on breast cancer outcomes. Compared to non-carriers, patients who carried a BRCA mutation indicated similar survival. However, with triple-negative breast cancer, the carriers might have a survival advantage during the first few years after diagnosis. They recommend considering patient prognosis associated with the first malignancy and patient preferences while making decisions about the timing of additional surgery aimed at reducing future second primary-cancer risks.